INTERCEPT PHARMACEUTICALS, INC. Business Finance Contracts & Agreements

Form of Exchange Agreement for the 2026 Notes (Filed With SEC on August 19, 2022)

Share Purchase Agreement, dated May 5, 2022, between Intercept Pharmaceuticals, Inc. (ICPT Inc.) as seller and Mercury Pharma Group Limited (Mercury Pharma) as purchaser (Filed With SEC on August 3, 2022)

Safety Data Exchange Agreement, dated May 5, 2022, between ICPT Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Amendment to Safety Data Exchange Agreement, dated July 1, 2022, between ICPT Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Amendment to Share Purchase Agreement, dated July 1, 2022, between ICPT Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Form of Stock Option Grant Notice and Agreement for Employees and Consultants (Filed With SEC on August 3, 2022)

Form of Stock Option Grant Notice and Agreement for Directors (Filed With SEC on August 3, 2022)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Employees and Consultants (Filed With SEC on August 3, 2022)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Directors (Filed With SEC on August 3, 2022)

Indenture, dated as of August 17, 2021, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee (Filed With SEC on August 23, 2021)

First Supplemental Indenture, dated as of August 17, 2021, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee and as collateral agent (Filed With SEC on August 23, 2021)

Security Agreement, dated as of August 17, 2021, among Intercept Pharmaceuticals, Inc., the Guarantors that may from time to time be a party thereto and U.S. Bank National... (Filed With SEC on August 23, 2021)

Form of Stock Option Grant Notice and Agreement for Directors (Filed With SEC on August 10, 2020)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Directors (Filed With SEC on August 10, 2020)

Form of Stock Option Grant Notice and Agreement for Employees and Consultants (Filed With SEC on February 25, 2020)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Employees and Consultants (Filed With SEC on February 25, 2020)

Common Stock Underwriting Agreement, dated May 9, 2019, between Intercept Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC,... (Filed With SEC on May 14, 2019)

Convertible Notes Underwriting Agreement, dated May 9, 2019, between Intercept Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC, Credit Suisse Securities (USA) LLC and Jefferies... (Filed With SEC on May 14, 2019)

Securities Purchase Agreement, dated May 8, 2019, between Intercept Pharmaceuticals, Inc. and Samsara BioCapital, L.P (Filed With SEC on May 14, 2019)

Second Supplemental Indenture, dated as of May 14, 2019, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee (including the form of 2.00%... (Filed With SEC on May 14, 2019)

Form of Stock Option Grant Notice and Agreement for Employees and Consultants (Filed With SEC on May 8, 2019)

Form of Restricted Stock Unit Grant Notice and Agreement for Employees and Consultants (Filed With SEC on May 8, 2019)

Underwriting Agreement, dated April 5, 2018, between Intercept Pharmaceuticals, Inc. and Credit Suisse Securities (USA) LLC and Jefferies LLC (Filed With SEC on April 10, 2018)

Securities Purchase Agreement, dated April 4, 2018, between Intercept Pharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on April 10, 2018)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) $400,000,000 3.25% Convertible Senior Notes due 2023 UNDERWRITING AGREEMENT (Filed With SEC on July 6, 2016)

INTERCEPTPharmaceuticals, Inc. and U.S.Bank National Association, as Trustee INDENTURE Dated as of July 6, 2016 SENIOR DEBT SECURITIES (Filed With SEC on July 6, 2016)

INTERCEPT PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of July 6, 2016 to Indenture for Senior Debt Securities Dated... (Filed With SEC on July 6, 2016)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) 1,200,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 2, 2015)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) 1,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on February 6, 2015)

INTERCEPTPHARMACEUTICALS, INC.4 (a Delawarecorporation) 1,000,000Shares of Common Stock UNDERWRITINGAGREEMENT (Filed With SEC on April 4, 2014)

*** OMITTED AND FILED SEPARATELY WITHTHE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER17 C.F.R. SECTION 240.24b-2 AMENDMENT N°4 TO PRODUCT RESEARCH,... (Filed With SEC on January 2, 2014)

*** OMITTED AND FILED SEPARATELY WITHTHE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO CONSULTING AND... (Filed With SEC on January 2, 2014)

*** OMITTED AND FILED SEPARATELY WITHTHE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO RESEARCH AND... (Filed With SEC on January 2, 2014)

INTERCEPTPHARMACEUTICALS, INC. (a Delawarecorporation) [________]Shares of Common Stock UNDERWRITINGAGREEMENT (Filed With SEC on October 8, 2013)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) [l]Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. Restricted Stock Unit Award Grant Noticefor Directors Restricted Stock Unit Award Grant underthe Company’s 2012 EquityIncentive Plan (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. Restricted Stock Unit Award Grant Noticefor Employees and Consultants Restricted Stock Unit Award Grant underthe Company’s 2012 EquityIncentive... (Filed With SEC on September 27, 2012)

THIS WARRANT AND THESHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)

THIS WARRANT AND THESHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECTTO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)

THIS WARRANT AND THE SHARESOF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)